Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity

Chemico-Biological Interactions

Volumn 237, Issue , 2015, Pages 66-72

  Niu, Mingshan ^a   Xu, Xiaoyu ^a   Shen, Yangling ^a   Yao, Yao ^a   Qiao, Jianlin ^a   Zhu, Feng ^a   Zeng, Lingyu ^a   Liu, Xuejiao ^a   Xu, Kailin ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Anti cancer; CRM1; Nuclear protein export; Piperlongumine

Indexed keywords

ALKALOID DERIVATIVE; ANTINEOPLASTIC AGENT; EXPORTIN 1; I KAPPA B ALPHA; PIPERLONGUMINE; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR FKHR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; PIPERLONGUMININE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; PROTEIN ANALYSIS; PROTEIN FUNCTION; CELL NUCLEUS; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; HELA CELL LINE; MASS SPECTROMETRY; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; CELL NUCLEUS; DIOXOLANES; HELA CELLS; HUMANS; MICROSCOPY, FLUORESCENCE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84930671154     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2015.05.016     Document Type: Article

References (30)

1. D.P. Bezerra, C. Pessoa, M.O. de Moraes, N. Saker-Neto, E.R. Silveira, and L.V. Costa-Lotufo Overview of the therapeutic potential of piplartine (piperlongumine) Eur. J. Pharm. Sci. 48 2013 453 463
2. H.M. Navickiene, A.C. Alecio, M.J. Kato, V.D. Bolzani, M.C. Young, and A.J. Cavalheiro Antifungal amides from Piper hispidum and Piper tuberculatum Phytochemistry 55 2000 621 626
3. Y. Wang, J.W. Wang, X. Xiao, Y. Shan, B. Xue, and G. Jiang Piperlongumine induces autophagy by targeting p38 signaling Cell Death Dis. 4 2013 e824
4. D.J. Adams, M. Dai, G. Pellegrino, B.K. Wagner, A.M. Stern, and A.F. Shamji Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs Proc. Natl. Acad. Sci. U. S. A. 109 2012 15115 15120
5. L.H. Gong, X.X. Chen, H. Wang, Q.W. Jiang, S.S. Pan, and J.G. Qiu Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells Oxid. Med. Cell. Longev. 2014 2014 906804
6. J. Ryu, M.J. Kim, T.O. Kim, T.L. Huh, and S.E. Lee Piperlongumine as a potential activator of AMP-activated protein kinase in HepG2 cells Nat. Prod. Res. 28 2014 2040 2043
7. L. Raj, T. Ide, A.U. Gurkar, M. Foley, M. Schenone, and X. Li Selective killing of cancer cells by a small molecule targeting the stress response to ROS Nature 475 2011 231 234
8. S. Ginzburg, K.V. Golovine, P.B. Makhov, R.G. Uzzo, A. Kutikov, and V.M. Kolenko Piperlongumine inhibits NF-kappaB activity and attenuates aggressive growth characteristics of prostate cancer cells Prostate 74 2014 177 186
9. Q.R. Liu, J.M. Liu, Y. Chen, X.Q. Xie, X.X. Xiong, and X.Y. Qiu Piperlongumine inhibits migration of glioblastoma cells via activation of ROS-dependent p38 and JNK signaling pathways Oxid. Med. Cell. Longev. 2014 2014 653732
10. S. Shrivastava, P. Kulkarni, D. Thummuri, M.K. Jeengar, V.G. Naidu, and M. Alvala Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells Apoptosis 19 2014 1148 1164
11. H.O. Jin, Y.H. Lee, J.A. Park, H.N. Lee, J.H. Kim, and J.Y. Kim Piperlongumine induces cell death through ROS-mediated CHOP activation and potentiates TRAIL-induced cell death in breast cancer cells J. Cancer Res. Clin. Oncol. 140 2014 2039 2046
12. U. Bharadwaj, T.K. Eckols, M. Kolosov, M.M. Kasembeli, A. Adam, and D. Torres Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer Oncogene 2014
13. F. Zanella, N.R. Dos Santos, and W. Link Moving to the core: spatiotemporal analysis of Forkhead box O (FOXO) and nuclear factor-kappaB (NF-kappaB) nuclear translocation Traffic 14 2013 247 258
14. H.Y. Fung, and Y.M. Chook Atomic basis of CRM1-cargo recognition, release and inhibition Semin. Cancer Biol. 27 2014 52 61
15. J.G. Turner, J. Dawson, C.L. Cubitt, R. Baz, and D.M. Sullivan Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents Semin. Cancer Biol. 27 2014 62 73
16. L. Al-Anati, S. Kadekar, J. Hogberg, and U. Stenius PCB153, TCDD and estradiol compromise the benzo[a]pyrene-induced p53-response via FoxO3a Chem. Biol. Interact. 219 2014 159 167
17. C. Balachandran, B. Sangeetha, V. Duraipandiyan, M.K. Raj, S. Ignacimuthu, and N.A. Al-Dhabi A flavonoid isolated from Streptomyces sp. (ERINLG-4) induces apoptosis in human lung cancer A549 cells through p53 and cytochrome c release caspase dependant pathway Chem. Biol. Interact. 224 2014 24 35
18. K. Parikh, S. Cang, A. Sekhri, and D. Liu Selective inhibitors of nuclear export (SINE)-a novel class of anti-cancer agents J. Hematol. Oncol. 7 2014 78
19. J.G. Turner, J. Dawson, and D.M. Sullivan Nuclear export of proteins and drug resistance in cancer Biochem. Pharmacol. 83 2012 1021 1032
20. K. Sakakibara, N. Saito, T. Sato, A. Suzuki, Y. Hasegawa, and J.M. Friedman CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity Blood 118 2011 3922 3931
21. X. Liu, M. Niu, X. Xu, W. Cai, L. Zeng, and X. Zhou CRM1 is a direct cellular target of the natural anti-cancer agent plumbagin J. Pharmacol. Sci. 124 2014 486 493
22. N. Kudo, N. Matsumori, H. Taoka, D. Fujiwara, E.P. Schreiner, and B. Wolff Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region Proc. Natl. Acad. Sci. U. S. A. 96 1999 9112 9117
23. M. Niu, Y. Sun, X. Liu, L. Tang, and R. Qiu Tautomycetin induces apoptosis by inactivating Akt through a PP1-independent signaling pathway in human breast cancer cells J. Pharmacol. Sci. 121 2013 17 24
24. M. Hilliard, C. Frohnert, C. Spillner, S. Marcone, A. Nath, and T. Lampe The anti-inflammatory prostaglandin 15-deoxy-delta(12,14)-PGJ2 inhibits CRM1-dependent nuclear protein export J. Biol. Chem. 285 2010 22202 22210
25. A.S. Azmi, A. Aboukameel, B. Bao, F.H. Sarkar, P.A. Philip, and M. Kauffman Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice Gastroenterology 144 2013 447 456
26. C. Yuan, L. Wang, L. Zhou, and Z. Fu The function of FOXO1 in the late phases of the cell cycle is suppressed by PLK1-mediated phosphorylation Cell Cycle 13 2014 807 819
27. A. Mor, M.A. White, and B.M. Fontoura Nuclear trafficking in health and disease Curr. Opin. Cell Biol. 28 2014 28 35
28. S.C. Mutka, W.Q. Yang, S.D. Dong, S.L. Ward, D.A. Craig, and P.B. Timmermans Identification of nuclear export inhibitors with potent anticancer activity in vivo Cancer Res. 69 2009 510 517
29. Y.T. Tai, Y. Landesman, C. Acharya, Y. Calle, M.Y. Zhong, and M. Cea CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications Leukemia 28 2014 155 165
30. S.S. Han, D.J. Son, H. Yun, N.L. Kamberos, and S. Janz Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro Leuk. Res. 37 2013 146 154